Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bourdin (Montpellier, France), A. Menzies-Gow (London, United Kingdom), G. Chupp (New Haven, CT, United States of America), C. Ambrose (Gaithersburg, MD, United States of America), K. Kmita (Warsaw, Poland), J. Llanos-Ackert (Thousand Oaks, CA, United States of America), G. Colice (Gaithersburg, MD, United States of America), B. Cook (Gaithersburg, MD, United States of America). Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATOR. 1484

Member's Comments

No comment yet.

Related content which might interest you: Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003 Estimation of risk of osteoporosis based on inhaled and oral corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 409s Year: 2002 Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007 Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010 Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020 Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Patient-reported side effects of oral corticosteroids Source: International Congress 2018 – Medical education via the web and the internet Year: 2018 Effect of discontinuation and readministration of inhaled human insulin on pulmonary safety in adult diabetes patients Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma Source: Eur Respir J 2002; 20: Suppl. 38, 8s Year: 2002 Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001 Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012